Kala Pharmaceuticals, Inc. – LSE:0JQ2.L
Kala Pharmaceuticals stock price today
Kala Pharmaceuticals stock price monthly change
Kala Pharmaceuticals stock price quarterly change
Kala Pharmaceuticals stock price yearly change
Kala Pharmaceuticals key metrics
Market Cap | 27.80M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -15.15 |
Revenue | N/A |
EBITDA | -38.30M |
Income | -39.55M |
Revenue Q/Q | N/A |
Revenue Y/Y | -98.13% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKala Pharmaceuticals stock price history
Kala Pharmaceuticals stock forecast
Kala Pharmaceuticals financial statements
| Jun 2023 | 0 | -10.41M | |
|---|---|---|---|
| Sep 2023 | 0 | -8.70M | |
| Dec 2023 | 70K | -8.62M | -12324.29% |
| Mar 2024 | 0 | -11.80M |
| Dec 2023 | 70K | -8.62M | -12324.29% |
|---|---|---|---|
| Mar 2024 | 0 | -11.80M | |
| Oct 2025 | 0 | -4.58M | |
| Dec 2025 | 0 | -4.55M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 66500000 | 49.00M | 73.7% |
|---|---|---|---|
| Sep 2023 | 61120000 | 49.89M | 81.64% |
| Dec 2023 | 55949000 | 48.44M | 86.59% |
| Mar 2024 | 53033000 | 46.37M | 87.44% |
| Jun 2023 | -7.59M | -10.03M | 3.07M |
|---|---|---|---|
| Sep 2023 | -2.95M | 9.71M | 40K |
| Dec 2023 | -7.69M | -7K | 2.53M |
| Mar 2024 | -10.84M | -13K | 8.44M |
Kala Pharmaceuticals alternative data
| Aug 2023 | 34 |
|---|---|
| Sep 2023 | 34 |
| Oct 2023 | 34 |
| Nov 2023 | 34 |
| Dec 2023 | 34 |
| Jan 2024 | 34 |
| Feb 2024 | 34 |
| Mar 2024 | 34 |
| Apr 2024 | 34 |
| May 2024 | 43 |
| Jun 2024 | 43 |
| Jul 2024 | 43 |
Kala Pharmaceuticals other data
| Insider | Compensation |
|---|---|
| Mr. Mark T. Iwicki (1966) Chairman, Pres & Chief Executive Officer | $871,140 |
Mr. Eric L. Trachtenberg (1973) Gen. Counsel, Chief Compliance Officer & Corporation Sec. | $646,560 |
| Mr. Todd Bazemore (1970) Chief Operating Officer | $607,500 |
Dr. Kim Brazzell Chief Medical Officer | |
Dr. Justin Hanes Ph.D. Founder & Chair of the Scientific Advisory Board | |
Dr. Hongming Chen Sc.D. Chief Scientific Officer | |
Ms. Mary Reumuth CPA, CPA Chief Financial Officer & Treasurer | |
Ms. Kathleen McCann Kline Vice President of Marketing | |
| Ms. Michele LaRussa Senior Vice President of Regulatory Affairs & Quality Assurance | |
Mr. Vincent Kosewski Senior Vice President of Manufacturing & Supply Chain Management |
-
What's the price of Kala Pharmaceuticals stock today?
One share of Kala Pharmaceuticals stock can currently be purchased for approximately $1.32.
-
When is Kala Pharmaceuticals's next earnings date?
Unfortunately, Kala Pharmaceuticals's (0JQ2.L) next earnings date is currently unknown.
-
Does Kala Pharmaceuticals pay dividends?
No, Kala Pharmaceuticals does not pay dividends.
-
How much money does Kala Pharmaceuticals make?
Kala Pharmaceuticals has a market capitalization of 27.80M.
-
What is Kala Pharmaceuticals's stock symbol?
Kala Pharmaceuticals, Inc. is traded on the LSE under the ticker symbol "0JQ2.L".
-
What is Kala Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Kala Pharmaceuticals?
Shares of Kala Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kala Pharmaceuticals's key executives?
Kala Pharmaceuticals's management team includes the following people:
- Mr. Mark T. Iwicki Chairman, Pres & Chief Executive Officer(age: 59, pay: $871,140)
- Mr. Eric L. Trachtenberg Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 52, pay: $646,560)
- Mr. Todd Bazemore Chief Operating Officer(age: 55, pay: $607,500)
- Dr. Kim Brazzell Chief Medical Officer
- Dr. Justin Hanes Ph.D. Founder & Chair of the Scientific Advisory Board
- Dr. Hongming Chen Sc.D. Chief Scientific Officer
- Ms. Mary Reumuth CPA, CPA Chief Financial Officer & Treasurer
- Ms. Kathleen McCann Kline Vice President of Marketing
- Ms. Michele LaRussa Senior Vice President of Regulatory Affairs & Quality Assurance
- Mr. Vincent Kosewski Senior Vice President of Manufacturing & Supply Chain Management
-
Is Kala Pharmaceuticals founder-led company?
Yes, Kala Pharmaceuticals is a company led by its founder Dr. Justin Hanes Ph.D..
-
How many employees does Kala Pharmaceuticals have?
As Jul 2024, Kala Pharmaceuticals employs 43 workers, which is 26% more then previous quarter.
-
When Kala Pharmaceuticals went public?
Kala Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Kala Pharmaceuticals's official website?
The official website for Kala Pharmaceuticals is kalarx.com.
-
Where are Kala Pharmaceuticals's headquarters?
Kala Pharmaceuticals is headquartered at 1167 Massachusetts Avenue, Arlington, MA.
-
How can i contact Kala Pharmaceuticals?
Kala Pharmaceuticals's mailing address is 1167 Massachusetts Avenue, Arlington, MA and company can be reached via phone at +7 819965252.
Kala Pharmaceuticals company profile:
Kala Pharmaceuticals, Inc.
kalarx.comLSE
43
Medical - Pharmaceuticals
Healthcare
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Arlington, MA 02476
:
ISIN: US4831192020
CUSIP: 483119202
